Variation of candidate genes in triglyceride metabolism

European Journal of Preventive Cardiology

Volumn 7, Issue 5, 2000, Pages 309-315

  Busch, Christopher P ^a   Hegele, Robert A ^a  

^a NONE   (United States)

Author keywords

atherosclerosis; environment; lipids; polygenic traits

Indexed keywords

APOLIPOPROTEIN C3; CHYLOMICRON; ENZYME VARIANT; GENE PRODUCT; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

AGE; GENDER; GENETIC VARIABILITY; HORMONE SUBSTITUTION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; ISCHEMIC HEART DISEASE; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

CORONARY DISEASE; GENETIC SCREENING; HUMANS; LIPOPROTEIN LIPASE; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES; VARIATION (GENETICS);

EID: 84910146942     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/204748730000700503     Document Type: Review

References (59)

1. Hegele RA. The pathogenesis of atherosclerosis. Clin Chim Acta. 1996 ; 246: 21-38
2. Hegele RA. Small genetic effects in complex diseases: a review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis. Clin Biochem. 1997 ; 30: 183-188
3. Erkelens DW. Metabolic basis for hypertriglyceridaemia in familial combined hyperlipidaemia. Eur Heart J. 1998 ; 19: H23- H26
4. Mead JR, Cryer A, Ramji DP. Lipoprotein lipase, a key role in atherosclerosis?. FEBS Lett. 1999 ; 462: 1-6
5. Semenkovich CF, Chen S-H, Wims M, Luo C-C, Li W-H, Chan L. Lipoprotein lipase and hepatic lipase mRNA tissue specific expression, developmental regulation, and evolution. J Lipid Res. 1989 ; 30: 423-431
6. Eisenberg S, Sehayek E, Olivecrona T, Vlodavsky I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest. 1992 ; 90: 2013-2021
7. Havel RJ, Kane JP. The inherited basis of metabolic disease. Scriver C Beaudet A Sly W Valle D, ed. New York: McGraw-Hill ; 1995: 1841-1851.
8. Santamarina-Fojo S, Dugi KA. Structure, function and role of lipoprotein lipase in lipoprotein metabolism. Curr Opin Lipidol. 1994 ; 5: 117-125
9. Salinem S, Lo J-Y, Mims MP, Zsigmond E, Smith LC, Chan L. Structure-function relationship of lipoprotein lipase-mediated enhancement of very low density lipoprotein binding and catabolism by the low density lipoprotein receptor. J Biol Chem. 1996 ; 271: 21906-21911
10. Gotto AM, Pownall HJ. Manual of lipid disorders: reducing the risk for coronary heart disease. 2 nd ed. Baltimore: Williams & Wilkins; 1999. pp. 102-105. Baltimore: Williams & Wilkins ; 1999: 102-105.
11. Benlian P, DeGennes JL, Foubert L, Zhang H, Gagne SE, Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med. 1996 ; 335: 848-854
12. Miesenbock G, Holzl B, Foger B, Brandstatter E, Paulweber B, Sandhofer F, et al. Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. J Clin Invest. 1993 ; 91: 448-454
13. Gerdes C, Fisher RM, Nicaud V, Boer J, Humphries SE, Talmud PJ, Faergeman O. Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations. Circulation. 1997 ; 96: 733-740
14. Humphries SE, Nicaud V, Margalef J, Tiret L, Talmud PJ. Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides. Arterioscler Thromb Vasc Biol. 1998 ; 18: 526-534
15. Patsch J. Influence of lipolysis on chylomicron clearance and HDL cholesterol levels. Eur Heart J. 1998 ; 19: H2- H6
16. Gaudet D, Vohl M-C, Julien P, Tremblay G, Perron P, Gagne C, et al. Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians. Am J Cardiol. 1998 ; 82: 299-305
17. Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem. 1995 ; 41: 153-158
18. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb. 1992 ; 12: 1336-1345
19. Karpe F. Mechanisms of postprandial hyperlipidaemia- remnants and coronary artery disease. Diabetic Med. 1997 ; 14: S60- S66
20. Hokanson JE, Brunzell JD, Jarvik GP, Wijsman EM, Austin MA. Linkage of low-density lipoprotein size to the lipoprotein lipase gene in heterozygous lipoprotein lipase deficiency. Am J Hum Genet. 1999 ; 64: 608-618
21. Austin MA. Genetic epidemiology of low-density lipoprotein subclass phenotypes. Ann Med. 1992 ; 24: 477-481
22. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990 ; 82: 495-506
23. Murthy V, Julien P, Gagne C. Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol Ther. 1996 ; 70: 101-135
24. Bijvoet S, Gagne SE, Moorjani S, Gagne C, Henderson HE, Fruchart J-C, et al. Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in heterozygotes for lipoprotein lipase deficiency. J Lipid Res. 1996 ; 37: 640-649
25. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A. Heterozygous lipoprotein lipase deficiency. Circulation. 1997 ; 96: 1737-1744
26. Minnich A, Baloukas J, Roederer G, Lussier-Cacan S, Davignon J, Genest J. Lipoprotein lipase gene mutations in coronary artery disease. Can J Cardiol. 1998 ; 14: 711-716
27. Hokanson JE. Lipoprotein lipase gene variants and risk of coronary disease: a quantitative analysis of population-based studies. Int J Clin Lab Res. 1997 ; 27: 24-34
28. Hokanson JE. Functional variants in the lipoprotein lipase gene and risk of cardiovascular disease. Curr Opin Lipidol. 1999 ; 10: 393-399
29. Henderson HE, Kastelein JJP, Zwinderman AH, Gagne E, Jukema JW, Reymer PWA, et al. Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. J Lipid Res. 1999 ; 40: 735-743
30. Chuang SS, Das HK. Identification of trans-acting factors that interact with cis-acting elements present in the first nontranslated exon of the human apolipoprotein B gene. Biochem Biophys Res Commun. 1996 ; 220: 553-562
31. Kastelein JJP, Groenemeyer BE, Hallman DM, Henderson H, Reymer PWA, Gagne SE, et al. The Asn9 variant of lipoprotein lipase is associated with the-93G promoter mutation and an increased risk of coronary artery disease. Clin Genet. 1998 ; 53: 27-33
32. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996 ; 3: 213-219
33. Ehrenborg E, Clee SM, Pimstone SN, Reymer PW, Benlian P, Hoogendijk CF, et al. Ethnic variation and in vivo effects of the-93t- > g promoter variant in the lipoprotein lipase gene. Arterioscler Thromb Vasc Biol. 1997 ; 17: 2672-2678
34. Hoffer MJ, Bredie SJ, Snieder H, Reymer PW, Demacker PN, Havekes LM, et al. Gender-related association between the-93T- > G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia. Atherosclerosis. 1998 ; 138: 91-99
35. Talmud PJ, Hall S, Holleran S, Ramakrishnan R, Ginsberg HN, Humphries SE. LPL promoter-93T/G transition influences fasting and postprandial plasma triglycerides response in African-American and Hispanics. J Lipid Res. 1998 ; 39: 1189-1196
36. Wittrup HH, Tybjaerg-Hansen A, Steffensen F, Deeb SS, Brunzell JD, Jensen G, et al. Mutations in lipoprotein lipase gene associated with ischemic heart disease in men. Arterioscler Thromb Vasc Biol. 1999 ; 19: 1535-1540
37. Wittrup HH, Tybaerg-Hansen A, Abildbaard S, Steffensen F, Schnohr P, Nordestgaard BG. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest. 1997 ; 99: 1606-1613
38. Hegele RA, Brunt JH, Connelly PW. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. Arterioscler Thromb Vasc Biol. 1995 ; 15: 861-871
39. Stepanov VA, Puzyre VP, Karpov RS, Kutmin AI. Genetic markers in coronary artery disease in a Russian population. Hum Biol. 1998 ; 70: 47-57
40. Anderson JL, King GJ, Bair TL, Elmer SP, Muhlestein JB, Habashi J, et al. Association of lipoprotein lipase gene polymorphisms with coronary artery disease. J Am Coll Cardiol. 1999 ; 33: 1013-1020
41. Ye P, Pei L, Wang S. Polymorphisms of the human lipoprotein lipase gene: possible association with lipid levels in patients with coronary heart disease in Beijing area. Chinese Med Sci J. 1996 ; 11: 157-161
42. Jemaa R, Tuzet S, Betoulle D, Apfelbaum M, Fumeron F. HindIII polymorphism of the lipoprotein lipase gene and plasma lipid response to low calorie diet. Int J Obesity Rel Metab Disord. 1997 ; 21: 280-283
43. Syvanne M, Talmud PJ, Humphries SE, Fisher RM, Rosseneu M, Hilden H, Taskinen M-R. Determinants of postprandial lipemia in men with coronary artery disease and low levels of HDL cholesterol. J Lipid Res. 1997 ; 38: 1463-1472
44. Peacock RE, Hamsten A, Ehle P Nisson, Humphries SE. Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden. Atherosclerosis. 1992 ; 97: 171-185
45. Kuivenhoven JA, Groenemeyer BE, Boer JM, Reymer PW, Berghuis R, Bruin T, et al. Ser447stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males. Arterioscler Thromb Vasc Biol. 1997 ; 17: 595-599
46. Groenemeijer BE, Hallman MD, Reymer PWA, Gagne E, Kuivenhoven JA, Bruin T, et al. Genetic variant showing a positive interaction with $-blocking agents with beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. Circulation. 1997 ; 95: 2628-2635
47. Rees A, Stocks J, Sharpe CR, Vella MA, Shoulders CC, Katz J, et al. Deoxyribonucleic acid polymorphism in the apolipoprotein A-I-C-III gene cluster. Association with hypertriglyceridemia. J Clin Invest. 1985 ; 76: 1090-1095
48. Tas S. Strong association of a single nucleotide substitution in the 3-untranslated region of the apolipoprotein-C-III gene with common hypertriglyceridemia in Arabs. Clin Chem. 1989 ; 35: 256-259
49. Zeng Q, Dammerman M, Takada Y, Matsunaga A, Breslow JL, Sasaki J. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population. Hum Hered. 1994 ; 95: 371-375
50. Hegele RA, Breslow JL. Apolipoprotein genetic variation in the assessment of atherosclerosis susceptibility. Genetic Epidemiol. 1987 ; 4: 163-184
51. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apolipoprotein CIII gene expression in transgenic mice. Science. 1990 ; 249: 790-793
52. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3-untranslated region polymorphisms. Proc Natl Acad Sci USA. 1993 ; 90: 4562-4566
53. Li WW, Dammerman MM, Smith JD, Metzger J, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 1995 ; 96: 2601-2605
54. Hegele RA, Connelly PW, Hanley AJG, Sun F, Harris SB, Zinman B. Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians. Arterioscler Thromb Vasc Biol. 1997 ; 17: 1060-1066
55. Talmud PJ, Humphries SE. Apolipoprotein C-III gene variation and dyslipidemia. Curr Opin Lipidol. 1997 ; 8: 154-158
56. Connelly PW, Hegele RA. Hepatic lipase deficiency. Crit Rev Clin Lab Sci. 1998 ; 35: 547-572
57. Hegele RA, Zinman B, Hanley AJG, Harris SH, Connelly PW. A common mtDNA polymorphism associated with variation in plasma triglyceride concentration. Am J Hum Genet. 1997 ; 60: 1552-1555
58. Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 2000 ; 9: 109-112
59. Fernandez-Real JM, Broch M, Vendrell J, Richart C, Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab. 2000 ; 85: 1334-1339